Phio Pharmaceuticals Corp. (PHIO) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential
Current Price
$1.14
Price Target
—
Target Range
— — —
Analyst Rating
—
Forward P/E—
Trailing P/E-0.8x
Forward PEG—
Implied Growth—
Median Target—
Analyst Spread—
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$—
—
Consensus
$—
—
Bull Case
$—
—
PHIO Price Target Analysis
Updated May 8, 2026As of May 8, 2026, Phio Pharmaceuticals Corp. (PHIO) has a Wall Street consensus price target of N/A, based on estimates from 0 covering analysts. The company has a market capitalization of $7M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is N/A, with 0 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, PHIO trades at a trailing P/E of -0.8x.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+22.6%
Avg Forward P/E22.2x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 SRPTSarepta Therapeutics, Inc. | $2.2B | $20.80 | $24.63 | +18.4% | Buy | 6.9x | 54 |
 ARWRArrowhead Pharmaceuticals, Inc. | $10.9B | $77.95 | $81.22 | +4.2% | Buy | — | 20 |
 ALNYAlnylam Pharmaceuticals, Inc. | $39.5B | $295.91 | $445.67 | +50.6% | Buy | 44.2x | 52 |
 NTLAIntellia Therapeutics, Inc. | $1.6B | $13.71 | $20.88 | +52.3% | Buy | — | 39 |
 BEAMBeam Therapeutics Inc. | $3.2B | $31.47 | $40.83 | +29.7% | Buy | — | 27 |
 EDITEditas Medicine, Inc. | $297M | $3.03 | $6.00 | +98.0% | Buy | — | 25 |
 CRSPCRISPR Therapeutics AG | $5.1B | $52.42 | $63.00 | +20.2% | Buy | — | 38 |
 IOVAIovance Biotherapeutics, Inc. | $1.3B | $3.55 | $2.00 | -43.7% | Buy | — | 20 |
 REGNRegeneron Pharmaceuticals, Inc. | $73.7B | $709.10 | $865.68 | +22.1% | Buy | 15.3x | 48 |
 MRNAModerna, Inc. | $19.3B | $48.54 | $36.00 | -25.8% | Hold | — | 27 |
Upside Potential Comparison
EDITNTLAALNYBEAMREGNCRSPSRPTARWRSee PHIO's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PHIO Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PHIO vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPHIO — Frequently Asked Questions
Quick answers to the most common questions about buying PHIO stock.
What is the PHIO stock price target for 2026?
The consensus price target for PHIO is $N/A, close to the current price of $1.14 (N/A% implied move). Based on 0 analyst estimates, the stock appears fairly valued near current levels.
Is PHIO a buy, sell, or hold?
PHIO has a consensus rating of "N/A" based on 0 Wall Street analysts. The rating breakdown is mixed, with 0 Hold ratings making up the largest segment. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
Is PHIO stock overvalued or undervalued?
PHIO's current price is $1.14 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
How high can PHIO stock go?
The most bullish Wall Street analyst has a price target of $N/A for PHIO, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
How many analysts cover PHIO stock?
PHIO is lightly followed, with 0 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 0 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the PHIO stock forecast?
The 12-month PHIO stock forecast based on 0 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "N/A".
Should I buy PHIO stock?
PHIO appears fairly valued according to analysts, with a "N/A" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do PHIO price targets vary so much?
PHIO analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.